Introduction {#s1}
============

Methicillin-resistant *Staphylococcus aureus* (MRSA) is a major public health concern and is responsible for both hospital- and community-associated infections worldwide (De Kraker et al., [@B33]; CDC, [@B23]; Falagas et al., [@B46]; Garza-González and Dowzicky, [@B51]; Lee et al., [@B69]; Chen and Huang, [@B27]). It is estimated that MRSA infections within the health care setting alone affected more than 150,000 patients annually in the European Union, with an additional cost of 380 million Euros (Köck et al., [@B68]). In the United States of America, 80,461 invasive MRSA infections and 11,285 related deaths occurred in 2011, and an estimated annual burden of between \$1.4 billion and 13.8 billion was attributed to community-acquired MRSA (CDC, [@B23]; Lee et al., [@B69]). Besides, MRSA has been established as a pathogen for domestic animals and linked with livestock-associated infections (Verkade and Kluytmans, [@B123]).

Methicillin resistance is usually due to the *mecA* gene, borne on the staphylococcal cassette chromosome *mec* (SCC*mec*) that codes for a 78-kDa penicillin binding protein (PBP2a), with decreased affinity to methicillin and all beta-lactam antibiotics (Chambers, [@B24]). To date, eleven SCC*mec* types have been identified (IWG-SCC, [@B60]). Some cassettes, for example, SCC*mec* II (53 kb) and SCC*mec* III (67 kb), are large and possess mobile genetic elements (MGE), such as integrated plasmids (pUB110, pI258, and pT181) and transposons (e.g., Tn554) (Ito et al., [@B58]), and are frequently associated with hospital-acquired MRSA (Ma et al., [@B73]; Ito et al., [@B59]). In contrast, SCC*mec* IV (21--24 kb) and V (27 kb) are shorter elements, generally susceptible to non-beta-lactam antibiotics, and linked with community MRSA (Chambers and Deleo, [@B25]). However, the spread of various MRSA clones between the hospital and community settings has made the dichotomous ranking difficult (Deurenberg and Stobberingh, [@B34]). Recently, a variant *mecA* gene (named *mecC*) which is situated on an SCC*mec* XI element has been described (Shore et al., [@B114]). It has a higher relative affinity for oxacillin as compared with cefoxitin (Kim et al., [@B66]), and exhibits only 69% sequence similarity at the nucleotide level and 63% amino-acid identity to *mec*A/PBP2a (Paterson et al., [@B93]). Furthermore, based on whole genome sequencing, mutations of the endogenous penicillin-binding proteins (PBP) 1, 2, and 3 in *mecA* and *mecC* negative strains have been postulated as a possible alternative mechanism for beta-lactam resistance in MRSA (Ba et al., [@B8]).

There is great interest in tracking, identifying and understanding the diversity of MRSA in various settings. Currently, the most widely used molecular techniques include *Staphylococcus* protein A gene typing (*spa*) and multilocus sequence typing (MLST). Studies (particularly using MLST) have provided evidence that a small set of lineages, clonal complex (CC)5, CC8, CC22, CC30, and CC45, are associated with most of the MRSA infections in hospitals (Stefani et al., [@B117]). Besides, a number of different geographically distinct lineages, CC1, CC8, CC30, and CC80, have also been associated with community MRSA infections (Chatterjee and Otto, [@B26]), while CC8 and CC30 have been identified as pandemic lineages both in the hospital and community setting (Chatterjee and Otto, [@B26]). Furthermore, regional clones have been described in Australia (sequence type \[ST\] 93) (Coombs et al., [@B31]), India (ST772) (D\'Souza et al., [@B36]; Shambat et al., [@B106]), South Korea (ST72) (Kim et al., [@B67]), Taiwan and China (ST59) (Chen and Huang, [@B27]).

The distribution of MRSA clones in Africa is not well-described. Understanding the molecular epidemiology of MRSA in Africa is important as a recent review indicated that since the year 2000, the prevalence of MRSA appears to be increasing in many African countries and pose a visible threat to the continent (Falagas et al., [@B46]). Furthermore, there is evidence of the replacement of existing MRSA clones with different and new clonal types in a number of countries (Conceição et al., [@B28]; Aires-de-Sousa et al., [@B3]; Albrecht et al., [@B4]; Espadinha et al., [@B44]; Lim et al., [@B71]; Nimmo et al., [@B83]) but information on this trend is lacking in Africa. The occurrence and changes in clonal identities, and their geographic spread is important to understand the spread and evolution of MRSA.

The Panton-Valentine Leukocidin (PVL) is a two-component pore-forming toxin with cytolytic activity on defined cells of the immune system (neutrophils, macrophages and monocytes) (Löffler et al., [@B72]; Yoong and Torres, [@B124]). It is encoded by the *lukS-PV* and *lukF-PV* genes (Boakes et al., [@B19]), and PVL-producing *S. aureus* exhibit a propensity for causing mainly severe and often recurrent skin and soft tissue infections (Shallcross et al., [@B105]). In addition, PVL-positive MRSA are associated with community onset-pneumonia (Vandenesch et al., [@B121]). Although the PVL genes are mainly carried by community-associated MRSA (CA-MRSA) (Vandenesch et al., [@B121]), data from West and Central Africa showed that at least 40% of clinical methicillin-susceptible *S. aureus* (MSSA) isolates in this region are PVL-positive (Breurec et al., [@B21]; Schaumburg et al., [@B102]; Shittu et al., [@B112]; Egyir et al., [@B37]). Therefore, the acquisition of the *mecA* gene by PVL-positive MSSA and the possible dissemination of PVL-positive CA-MRSA could present a significant challenge in disease management and infection control in resource-limited countries in Africa.

This systematic review examined published literature on the molecular epidemiology of MRSA in Africa. By summarizing currently available data on the continent, our objective was to describe the distribution of MRSA clones, the prevalence of PVL-positive MRSA, and to highlight the need to develop more comprehensive surveillance and reporting systems for multidrug-resistant organisms such as MRSA in Africa.

Methods {#s2}
=======

This systematic review was conducted in accordance with the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines (Moher et al., [@B77]).

Literature search strategy
--------------------------

The relevant English and French articles available in five electronic databases (MEDLINE, EBSCOhost, ISI Web of knowledge, Scopus, and African Journals Online) were retrieved by two authors using predefined search terms (Table [S1](#SM1){ref-type="supplementary-material"}). The literature search was conducted until 31 October 2014.

Eligible article identification
-------------------------------

Figure [1](#F1){ref-type="fig"} summarizes the study selection process. All duplicate articles were removed and data on MSSA as well as *in-vitro* studies were also excluded. The eligibility of published reports in this review was based primarily on polymerase chain reaction (PCR) detection of the *mecA* gene, and the use of at least one molecular tool for genotyping of MRSA strains (Table [1](#T1){ref-type="table"}). In addition, worldwide surveys that covered African countries were also included. An MRSA clone was defined based on the combination of MLST sequence type (ST) and SCC*mec* typing data as previously reported (Okuma et al., [@B86]). The nomenclature of the SCC*mec* types was as proposed by the International Working Group on the Classification of Staphylococcal Cassette Chromosome Elements (IWG-SCC, [@B60]). SCC*mec* elements that could not be classified were indicated as non-typeable (SCC*mec*-NT). In this study, we categorized MRSA into various CCs according to the current eBURST scheme, Version 3 (accessed 30 October 2014) (eBURST, [www.mlst.net](http://www.mlst.net), V3)[^1^](#fn0001){ref-type="fn"}.

![**Preferred reporting item for systematic reviews**. CONS, coagulase negative staphylococci; MSSA, methicillin susceptible *S. aureus;* MRSA, methicillin resistant *S. aureus.*](fmicb-06-00348-g0001){#F1}

###### 

**Characteristics of eligible articles that studied Methicillin resistant *Staphylococcus aureus***.

  **Country**                                    **Study period**        **Study population (sample type)**                                                                                     **No. of *S. aureus* isolates**                                          ***S. aureus* molecular identification**   **No. of MRSA[^¶^](#TN1){ref-type="table-fn"}**                         **Setting (no.)**   **Genotyping tools**   ***PVL***   **Detection of genes**   **References**                            
  ---------------------------------------------- ----------------------- ---------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------ ------------------------------------------ ----------------------------------------------------------------------- ------------------- ---------------------- ----------- ------------------------ ---------------- ---- ---- ---- ---- ---- ----------------------------------------------------------
  **STUDIES CONDUCTED IN HUMANS**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  Algeria                                        2003--2004              Clinical samples from hospitals and community                                                                          614                                                                      --                                         204                                                                     HA (40)/CA (21)     ✓                      --          ✓                        --               ✓    ✓    ✓    --   --   Ramdani-bouguessa et al., [@B95]
                                                 2004--2007              Human infections (in- and-out patients)                                                                                65                                                                       --                                         23                                                                      NR                  ✓                      --          --                       ✓                ✓    --   ✓    --   --   Bekkhoucha et al., [@B9]
                                                 2005--2007              From military hospital (Pus, venous catheter, tracheal aspirates, lumbar puncture fluid, blood culture and urine)      NR                                                                       --                                         64                                                                      HA (50)/CA (14)     ✓                      --          --                       --               --   --   ✓    --   ✓    Ouchenane et al., [@B90], [@B89]
                                                 2006--2007              Healthy and hospitalized individuals                                                                                   221[^α^](#TN2){ref-type="table-fn"} 52[^β^](#TN3){ref-type="table-fn"}   *gyrA* PCR                                 99[^α^](#TN2){ref-type="table-fn"} 23[^β^](#TN3){ref-type="table-fn"}   HA (65)/CA (84)     ✓                      --          ✓                        ✓                ✓    NR   ✓    --   ✓    Antri et al., [@B6]
                                                 2010--2011              Children and neonates (SSTI, bacteraemia, otitis and bone/joint infections)                                            129                                                                      --                                         25                                                                      HA (15)/CA (10)     ✓                      --          --                       --               ✓    ✓    ✓    --   --   Djoudi et al., [@B35]
  Angola                                         2012                    Nasal swabs from inpatients and HCW                                                                                    117                                                                      --                                         68                                                                      NR                  ✓                      --          ✓                        ✓                ✓    ✓    ✓    --   ✓    Conceição et al., [@B29]
  Egypt                                          2007--2008              Pus, sputum, wounds, abscess, blood, urine, and discharge                                                              NR                                                                       --                                         21                                                                      CA (4)              ✓                      ✓           ✓                        ✓                ✓    NR   ✓    --   ✓    Enany et al., [@B42]
                                                 NR                      SSTI and nasal swabs                                                                                                   38                                                                       --                                         18                                                                      CA (18)             ✓                      --          --                       --               --   --   ✓    --   --   Sobhy et al., [@B115]
                                                 NR                      Septic wounds, UTI and RTI (nasal swabs)                                                                               10                                                                       --                                         7                                                                       --                  --                     ✓           --                       ✓                --   --   --   --   --   El-Jakee et al., [@B40][^\*^](#TN6){ref-type="table-fn"}
  Gabon                                          2008--2010              asymptomatic carriers (nares, axillae, inguinal swabs) and patients (abscess, wound, blood and others)                 217                                                                      *nuc* and 16S rRNA PCR                     12                                                                      HA (6)/ CA (6)      ✓                      --          ✓                        ✓                ✓    --   ✓    --   ✓    Schaumburg et al., [@B102]; Ateba Ngoa et al., [@B7]
                                                 2010--2013              swabs from *S. aureus* carrier mothers (nasal and mammillary) and their infants (Nasal and pharyngeal)                 460                                                                      --                                         9                                                                       NR                  ✓                      --          --                       ✓                ✓    --   ✓    --   ✓    Schaumburg et al., [@B99]
                                                 NR                      Blood culture of one patient                                                                                           1                                                                        --                                         1                                                                       NR                  --                     --          --                       ✓                ✓    --   ✓    --   ✓    Huson et al., [@B57]
  Ghana                                          2011--2012              In-patients and hospital staff                                                                                         105                                                                      *spa* gene PCR                             6                                                                       NR                  ✓                      --          --                       ✓                ✓    --   ✓    --   --   Egyir et al., [@B38]
                                                 2010--2012              SSTI and blood samples from six hospitals                                                                              308                                                                      --                                         9                                                                       NR                  ✓                      --          --                       ✓                ✓    --   ✓    --   --   Egyir et al., [@B37]
                                                 2011--2012              Nasal swabs from apparently healthy carriers                                                                           124                                                                      --                                         2                                                                       HA (2)              ✓                      --          --                       ✓                ✓    --   ✓    --   --   Egyir et al., [@B39]
  Kenya                                          2005--2007              In and out-patients with SSTI boil, abscess, cellulitis and ulcer                                                      84                                                                       --                                         69                                                                      NR                  ✓                      --          --                       --               --   --   ✓    --   --   Maina et al., [@B74]
                                                 2011                    Nasal and axillary skin swabs from hospitalized patients                                                               85                                                                       --                                         6                                                                       NR                  ✓                      --          --                       ✓                ✓    --   ✓    ✓    ✓    Aiken et al., [@B2]
  Libya                                          2009--2010              Nasal swabs from in-patient children, their mothers, out-patient children and HCW                                      758                                                                      --                                         70                                                                      HA (12) CA (6)      --                     --          --                       --               --   ✓    ✓    --   --   Al-haddad et al., [@B5]
  Mali                                           2005                    Asymptomatic nasal carriers                                                                                            88                                                                       --                                         1                                                                       CA (1)              --                     --          --                       --               ✓    --   --   --   --   Ruimy et al., [@B98]
  Mozambique                                     2010--2011              Post-operative, burn wound infections, skin and soft tissue abscesses                                                  99                                                                       --                                         9                                                                       HA (8), CA (1)      --                     --          --                       ✓                --   --   ✓    ✓    --   Van der Meeren et al., [@B122]
  Nigeria                                        1998--2002              Wounds, aspirate, amniotic fluid                                                                                       276                                                                      --                                         4                                                                       NR                  ✓                      --          --                       --               ✓    ✓    --   --   --   Adesida et al., [@B1]
                                                 2002--2004              Wound samples, blood cultures, urine, otitis media and ocular related infections                                       200                                                                      --                                         3                                                                       NR                  ✓                      --          --                       --               --   ✓    --   --   --   Shittu and Lin, [@B109]
                                                 2007--2012              Clinical specimen                                                                                                      150                                                                      --                                         12                                                                      NR                  ✓                      --          --                       --               ✓    --   ✓    --   ✓    Okon et al., [@B84], [@B85]
                                                 2007                    Surgical and pediatric patients wound samples, corneal, conjunctival, auricular, genital and nasal swabs               346                                                                      --                                         70                                                                      HA (42), CA (28)    ✓                      --          ✓                        ✓                ✓    --   ✓    --   ✓    Ghebremedhin et al., [@B53]
                                                 2008--2010              HIV-positive and healthy individuals (nasal swabs)                                                                     202                                                                      --                                         26                                                                      NR                  --                     ✓           --                       ✓                ✓    --   ✓    --   --   Olalekan et al., [@B87]
                                                 2009                    Wound infections, semen, UTI, chronic ulcer, conjunctivitis, throat infections                                         68                                                                       --                                         11                                                                      NR                  ✓                      --          --                       ✓                ✓    --   ✓    ✓    --   Shittu et al., [@B112]
                                                 2009--2011              Patients and carriers                                                                                                  62                                                                       --                                         22                                                                      NR                  ✓                      --          --                       --               ✓    --   ✓    --   --   Raji et al., [@B94]
                                                 2010                    Clinical samples from patients with burns, septicaemia, wound infections, osteomyelitis, bronchitis and GIT            51                                                                       *tuf* gene PCR                             15                                                                      NR                  ✓                      --          --                       ✓                ✓    --   ✓    ✓    --   Shittu et al., [@B113]
                                                 NR                      Urine, blood and aspirates, wound, eye and ear, urethral and endocervical swab                                         116                                                                      --                                         48                                                                      HA (40), CA (8)     ✓                      --          --                       --               --   --   ✓    --   ✓    Terry Alli et al., [@B120]
  South Africa                                   2001--2003              Wound samples, sputum, otitis media and blood culture                                                                  227                                                                      *nuc* gene PCR                             61                                                                      NR                  ✓                      ✓           --                       --               --   ✓    --   ✓    --   Shittu and Lin, [@B108]; Shittu et al., [@B110]
                                                 2001--2003              Isolates from 16 laboratories in KZN                                                                                   241                                                                      --                                         24                                                                      NR                  ✓                      --          --                       --               ✓    --   --   --   --   Essa et al., [@B45]
                                                 2001--2003              Wounds, sputum, otitis media, urine and blood culture                                                                  NR                                                                       --                                         61                                                                      NR                  ✓                      --          --                       ✓                ✓    ✓    ✓    --   --   Shittu et al., [@B111]
                                                 2005--2006              Bacteraemia, SSTI, urine, catheter tip, cerebrospinal and drainage fluids                                              NR                                                                       --                                         320                                                                     HA                  ✓                      --          --                       ✓                ✓    ✓    ✓    --   ✓    Moodley et al., [@B79]
                                                 2006--2007              Clinical samples                                                                                                       NR                                                                       --                                         97                                                                      HA (79), CA (4)     ✓                      --          --                       ✓                --   --   ✓    --   --   Makgotlho et al., [@B75]
                                                 2007--2008 2007--2011   Pus and pus swabs, urine, blood, RTS and CVCT                                                                          NR                                                                       --                                         100                                                                     CA (10)             ✓                      --          --                       ✓                ✓    ✓    ✓    --   ✓    Jansen van Rensburg et al., [@B61], [@B62]
                                                 2009--2010              A wide range of clinical specimens mostly SSTI                                                                         367                                                                      --                                         56                                                                      NR                  ✓                      --          ✓                        ✓                ✓    ✓    ✓    --   --   Oosthuysen et al., [@B88]
  São Tome and Príncipe                          2010--2012              Patients and healthy carriers                                                                                          52                                                                       --                                         14                                                                      NR                  ✓                      --          ✓                        ✓                ✓    ✓    ✓    --   ✓    Conceição et al., [@B30]
  Tanzania                                       2008                    Wound, nasal swab and pus                                                                                              160                                                                      --                                         24                                                                      HA                  --                     --          --                       ✓                ✓    --   ✓    --   --   Moremi et al., [@B80]
                                                 2010                    Apparently healthy children under 5 years (nasal swabs)                                                                114                                                                      *nuc* gene PCR                             12                                                                      CA                  --                     --          --                       --               --   ✓    --   --   --   Moyo et al., [@B81]
  Tunisia                                        1998--2007              Clinical specimens from neutropenic patients                                                                           72                                                                       *nuc* gene PCR                             13                                                                      HA (13)             ✓                      --          --                       --               --   ✓    --   --   --   Bouchami et al., [@B20]
                                                 2002                    Patients who developed MRSA infections                                                                                 NR                                                                       --                                         6                                                                       HA (6)              --                     --          --                       --               --   ✓    --   --   --   Ben Ayed et al., [@B10]
                                                 2003--2004              Pus, blood, pleural fluid, venous catheter                                                                             NR                                                                       --                                         72                                                                      NR                  ✓                      --          ✓                        --               --   --   ✓    --   ✓    Ben Nejma et al., [@B16]
                                                 2003--2004              Pathological samples from different wards                                                                              147                                                                      --                                         19                                                                      NR                  --                     --          --                       --               --   ✓    --   --   --   Ben Saida et al., [@B17]
                                                 2003--2005              Pus and associated with cutaneous infections                                                                           NR                                                                       --                                         64                                                                      CA (64)             ✓                      --          ✓                        ✓                ✓    ✓    ✓    --   ✓    Ben Nejma et al., [@B15]
                                                 2004                    Cutaneous pus, blood cultures, urine and puncture fluids                                                               NR                                                                       --                                         34                                                                      HA (32), CA (2)     ✓                      --          --                       --               --   --   --   --   --   Ben Jomaa-Jemili et al., [@B12]
                                                 2004--2005              Cutaneous pus, RTS, urine, blood culture,                                                                              475                                                                      --                                         57                                                                      NR                  --                     --          ✓                        --               --   --   --   --   --   Ben Ayed et al., [@B11]
                                                 2004--2008              Samples from hospitals and community                                                                                   NR                                                                       --                                         69                                                                      HA (41), CA (28)    ✓                      --          ✓                        ✓                ✓    --   ✓    --   --   Ben Jomàa-Jemili et al., [@B13]
                                                 2006--2008              Children with CA invasive infections bacteraemia and osteomyelitis                                                     36                                                                       --                                         8                                                                       CA (8)              ✓                      --          ✓                        ✓                ✓    ✓    ✓    --   --   Kechrid et al., [@B65]
                                                 2007                    Pus and skin infections                                                                                                NR                                                                       --                                         11                                                                      CA (11)             ✓                      --          ✓                        ✓                ✓    ✓    ✓    --   --   Ben Nejma et al., [@B14]
                                                 2008                    Pus and blood culture (case report)                                                                                    2                                                                        --                                         2                                                                       NR                  ✓                      --          ✓                        ✓                ✓    --   ✓    --   ✓    Zribi et al., [@B126]
                                                 2008--2009              Humans in contact with animals                                                                                         55                                                                       --                                         1                                                                       CA (1)              ✓                      --          ✓                        ✓                ✓    --   ✓    ✓    ✓    Ben Slama et al., [@B18]
  Uganda                                         2009--2010              Swabs from patients, HCW and from hospital environment (sinks, door handles, surgical trays, bed and table surfaces)   41                                                                       --                                         41                                                                      NR                  ✓                      --          --                       --               --   --   ✓    ✓    ✓    Kateete et al., [@B64]
                                                 2011--2012              SSI                                                                                                                    64                                                                       *nuc* gene PCR                             24                                                                      NR                  ✓                      --          --                       ✓                --   --   ✓    --   --   Seni et al., [@B104]
  Multicenter[^\#^](#TN4){ref-type="table-fn"}   2007--2008              SSTI, bacteraemia/septicaemia, urine, wounds osteomyelitis and myositis                                                NR                                                                       --                                         86                                                                      CA (9), HA (77)     ✓                      --          ✓                        ✓                ✓    --   ✓    --   ✓    Breurec et al., [@B22]
  Multicentre[^✖^](#TN5){ref-type="table-fn"}    2004--2005              Uncomplicated skin infections                                                                                          292                                                                      --                                         105                                                                     HA (3)              ✓                      --          --                       --               ✓    ✓    ✓    --   --   Goering et al., [@B54]
  **STUDIES CONDUCTED IN ANIMALS**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  Egypt                                          NR                      Cows and buffaloes milk, cattle septic wounds                                                                          9                                                                        --                                         5                                                                       NR                  --                     ✓           --                       ✓                --   --   --   --   --   El-Jakee et al., [@B40][^\*^](#TN6){ref-type="table-fn"}
  Senegal                                        2009--2011              Pigs (nasal swabs)                                                                                                     73                                                                       --                                         6                                                                       NR                  ✓                      --          --                       ✓                ✓    --   ✓    --   ✓    Fall et al., [@B47]
  Tunisia                                        2010                    Healthy sheep (nasal swabs)                                                                                            73                                                                       --                                         5                                                                       CA (6)              ✓                      --          ✓                        ✓                ✓    ✓    --   --   ✓    Gharsa et al., [@B52]

agr, Accessory gene regulator; CA, Community-acquired methicillin-resistant S. aureus; coa, Coagulase gene; CVCT, Central venous catheter tips; GIT, Genital tract infections; gyrA, DNA gyrase gene; HA, Hospital-acquired methicillin resistant S. aureus; HCW, Health care workers; HIV, Human immunodeficiency virus; KZN, KwaZulu-Natal province; MLST, Multilocus locus sequence typing; MRSA, Methicillin-resistant Staphylococcus aureus; No., Number of isolates; NR, Not reported; nuc, Thermonuclease gene; PCR, Polymerase chain reaction; PFGE, Pulsed-field gel electrophoresis; PVL, Panton-Valentine-Leukocidin genes; SCCmec, Staphylococcal chromosomal cassette mec element; RTI, Respiratory tract infections; rRNA, Ribosomal ribonucleic acid; RTS, Respiratory tract specimens; spa, Staphylococcus aureus protein A gene; SSTI, Skin and soft tissue infections; SSI, Surgical site infections; tuf, Elongation factor tu; UTI, Urinary tract infections.

MRSA as confirmed by mecA PCR;

✓, Test was conducted; −, Test was not conducted;

Hospitalized individuals;

Nasal carrier study;

African multicenter study which included Cameroon, Madagascar, Morocco, Niger and Senegal;

An international multicenter study which included only South Africa;

Study was conducted in both animal and human host.

Data extraction and synthesis
-----------------------------

The relevant data were extracted from each of the articles as stated in Table [1](#T1){ref-type="table"}. Separate articles that analyzed the same *S. aureus* isolates but answered different questions were considered as a single study.

eBURST analysis
---------------

The relationship between the MRSA STs described in this review and other lineages reported world-wide was analyzed using the eBURST scheme. The allelic profiles were downloaded from the MLST website (<http://saureus.mlst.net/>) which included the African MRSA STs as well as 223 representative and randomly selected STs (from each CC) based on the differences in their allelic profiles. The minimum spanning tree was constructed by the goeBURST algorithm using the Phyloviz software v1.1 (<http://www.phyloviz.net/>).

Results {#s3}
=======

Literature search
-----------------

The systematic search of the five electronic databases yielded 1775 articles (Figure [1](#F1){ref-type="fig"}). No additional studies were identified from AJOL. After the removal of duplicate studies and assessment of titles and abstracts, 110 full-text articles were screened, of which 57 studies were considered eligible for the qualitative analysis according to our inclusion criteria.

Characteristics of the studies included in the systematic review
----------------------------------------------------------------

Most of the data analyzed were obtained from single center studies conducted mainly in five countries; Tunisia (*n* = 13), Nigeria (*n* = 9), South Africa (*n* = 7), Algeria (*n* = 5), and Egypt (*n* = 3) (Table [1](#T1){ref-type="table"}). Multicenter studies were only reported in two articles (Goering et al., [@B54]; Breurec et al., [@B22]), including a survey which comprised five African countries, Cameroon, Madagascar, Morocco, Niger and Senegal (Breurec et al., [@B22]), and an inter-continental multicenter study, which included South Africa (Goering et al., [@B54]). Only three studies investigated the detection of MRSA in animals (Table [1](#T1){ref-type="table"}).

In most of the reports included in this study, *S. aureus* was identified by phenotypic and culture characteristics, while molecular identification (16S rRNA, detection of the thermonuclease and the elongation factor tu - *nuc, tuf* - genes) was performed in only 12.3% (7/57). The screening for antibiotic resistance and toxin/virulence genes were carried out in seven and 22 studies, respectively (Table [1](#T1){ref-type="table"}). Furthermore, all the eligible studies analyzed MRSA using at least one genotyping technique, and 59.6% (34/57) provided adequate genotyping data on MRSA clones from 15 African countries (Tables [1](#T1){ref-type="table"}, [2](#T2){ref-type="table"}). Studies included in this systematic review did not investigate on the *mecC* gene.

###### 

**Methicillin resistant *Staphylococcus aureus* clones reported in 34 eligible studies**.

  **Country**    **Clonal type ST-SCC*mec***                       **Clonal complex**   ***spa* type**           **PVL status**   ***agr***   **References**
  -------------- ------------------------------------------------- -------------------- ------------------------ ---------------- ----------- ------------------------------------------------------
  Algeria        ST80-IV \[2B\]                                    80                   ND                       \+               III         Ramdani-bouguessa et al., [@B95]
                 ST37-IVa \[2B\]                                   30                   ND                       \+               III         
                 ST239-III \[3A\]                                  5                    ND                       −                I           
                 ST239-IVa \[2B\]                                  5                    ND                       −                I           
                 ST241-III \[3A\]                                  5                    ND                       −                I           
                 ST637-III \[3A\]                                  5                    ND                       −                I           
                 ST5-IV, IVa \[2B\]                                5                    ND                       +, −             II          
                 ST635-IV \[2B\]                                   80                   ND                       −                III         
                 ST636-NT                                          22                   ND                       −                I           
                 ST80-IV \[2B\]                                    80                   t044                     \+               ND          Bekkhoucha et al., [@B9]
                 ST239-III \[3A\]                                  5                    t037                     −                ND          
                 ST5-IVa \[2B\]                                    5                    t311, t450               −                ND          
                 ST88-NT                                           88                   t188, t267               −                ND          
                 ST80-IV \[2B\]                                    80                   t044, t4143              \+               III         Antri et al., [@B6]
                 ST241-III \[3A\]                                  5                    ND                       −                III         
                 ST8-V \[5C\]                                      5                    ND                       −                I           
                 ST80-IVc \[2B\]                                   80                   ND                       +, −             ND          Djoudi et al., [@B35]
                 ST39-II \[2A\]                                    30                   ND                       −                ND          
  Angola         ST5-IVa \[2B\]                                    5                    t105, t311, t11657       −                II          Conceição et al., [@B29]
                 ST8-IVd, V \[2B\]                                 5                    t104, t1774              −                I           
                 ST72-V \[5C\]                                     5                    t3092                    −                I           
                 ST88-IVa \[2B\]                                   88                   t186, t325, t786,        −                III         
                                                                                        t1951, t3869                                          
                 ST5-V \[5C\]                                      5                    t6065                    −                II          
                 ST2629-V \[5C\]                                   5                    t6065                    −                II          
                 ST789-V \[5C\]                                    7                    t091                     −                II          
  Cameroon       ST5-V \[5C\]                                      5                    t311                     \+               II          Breurec et al., [@B22]
                 ST88-IV \[2B\]                                    88                   t186                     −                III         
                 ST8-IV \[2B\]                                     5                    t024, t121, t451         \+               I           
                 ST1289-V \[5C\]                                   88                   t1339                    \+               III         
  Egypt          ST80-IVc \[2B\]                                   80                   t042, t044, t070, t983   \+               III         Enany et al., [@B42]
                 ST30-IVa \[2B\]                                   30                   t251, t318               \+               III         
                 ST1010-X^a^                                       121                  t159, t312               \+               IV          
  Gabon          ST8-IV \[2B\]                                     5                    t121                     \+               I           Schaumburg et al., [@B102]; Ateba Ngoa et al., [@B7]
                 ST88-IV \[2B\]                                    88                   t186                     −                III         
                 ST5-IV \[2B\]                                     5                    t653                     −                II          
                 ST5-IV \[2B\]                                     5                    t653                     −                ND          Schaumburg et al., [@B99]
                 ST8-NT                                            5                    t112, t121               \+               ND          
                 ST45-V \[5C\]                                     45                   t437, t8860              −                ND          
                 ST88-IV \[2B\]                                    88                   t4195                    −                ND          
  Ghana          ST72-V \[5C\]                                     5                    t537                     −                ND          Egyir et al., [@B38]
                 ST8-V \[5C\]                                      5                    t064                     −                ND          
                 ST88-IV \[2B\]                                    88                   t325, t1951, t2649       −                ND          
                 ST72-V \[5C\]                                     5                    t537                     −                ND          Egyir et al., [@B39]
                 ST8-IV \[2B\]                                     5                    t121                     \+               ND          
                 ST239-III \[3A\]                                  5                    t037                     −                ND          
                 ST250-I \[1B\]                                    5                    t928                     −                ND          
                 ST2021-V \[5C\]                                   5                    t024                     −                ND          
                 ST88-IV \[2B\]                                    88                   t186                     −                ND          
                 ST789-IV \[2B\]                                   7                    t547                     \+               ND          
                 ST508-V \[5C\]                                    45                   t5132                    −                ND          Egyir et al., [@B37]
  Kenya          ST239-III \[3A\]                                  5                    t037                     −                ND          Aiken et al., [@B2]
  Madagascar     ST8-IV \[2B\]                                     5                    t121                     \+               I           Breurec et al., [@B22]
                 ST30-V \[5C\]                                     30                   t4686                    −                III         
                 ST88-IV \[2B\]                                    88                   t186                     −                III         
  Morocco        ST239, ST241-III \[3A\]                           5                    t037, t138               −                I           
                 ST5-IV \[2B\]                                     5                    t311                     \+               II          
  Niger          ST239, ST241-III \[3A\]                           5                    t138                     −                I           
                 ST239, ST241-V \[5C\]                             5                    t037                     −                I           
                 ST88-IV \[2B\]                                    88                   t186                     −                III         
  Nigeria        ST8-IV \[2B\]                                     5                    ND                       −                ND          Adesida et al., [@B1]
                 ST88-IV \[2B\]                                    88                   t186                     \+               III         Ghebremedhin et al., [@B53]
                 ST241-IV \[2B\]                                   5                    t037                     −                I           
                 ST250-I \[1B\]                                    5                    t194, t292               −                I           
                 ST241-III \[3A\]                                  5                    t037                     −                ND          Shittu et al., [@B112]
                 ST8-V \[5C\]                                      5                    t064                     −                ND          
                 ST8-V \[5C\]                                      5                    t451                     −                ND          
                 ST94-IV \[2B\]                                    5                    t008                     −                ND          
                 ST5-V \[5C\]                                      5                    t002                     −                ND          
                 ST241-III \[3A\]                                  5                    t037                     −                ND          Shittu et al., [@B113]
                 ST88-IV \[2B\]                                    88                   t729, t1603              −                ND          
                 ST37-III \[3A\]                                   30                   t074                     −                ND          
                 ST39-II \[2A\]                                    30                   t007                     −                ND          
                 ST8-V \[5C\], IV \[2B\], ST8-NT                   5                    t064                     −                ND          
                 ST152-NT                                          152                  t4690                    \+               ND          
                 ST1-V \[5C\]                                      5                    ND                       \+               ND          Raji et al., [@B94]
                 ST239-III\[3A\]~*mercury*~                        5                    ND                       −                ND          
                 ST5-II \[2A\]                                     5                    ND                       −                ND          
                 ST8-V \[5C\]                                      5                    ND                       −                ND          
                 ST247-I \[1B\]                                    5                    ND                       −                ND          
                 ST772-V \[5C\]                                    5                    ND                       \+               ND          
                 ST88-IV \[2B\]                                    88                   ND                       −                ND          
                 ST241-III \[3A\]                                  5                    ND                       −                ND          Okon et al., [@B84]
  Senegal        ST5-IV \[2B\][^\*^](#TN7){ref-type="table-fn"}    5                    t311                     \+               ND          Fall et al., [@B47]
                 ST88-IV \[2B\][^\*^](#TN7){ref-type="table-fn"}   88                   t3489                    −                ND          
                 ST239, ST241-III \[3A\]                           5                    t037, t138               −                I           Breurec et al., [@B22]
                 ST5-II \[2A\]                                     5                    t311                     \+               II          
                 ST5-IV \[2B\]                                     5                    t311                     \+               II          
                 ST88-IV \[2B\]                                    88                   t168                     −                III         
  South Africa   ST5-IV \[2B\]                                     5                    ND                       ND               ND          Essa et al., [@B45]
                 ST8-IV \[2B\]                                     5                    ND                       ND               ND          
                 ST8-II \[2A\]                                     5                    ND                       ND               ND          
                 ST239-III \[3A\]                                  5                    ND                       ND               ND          
                 ST45-IV \[2B\]                                    45                   ND                       ND               ND          
                 ST612-IV \[2B\]                                   5                    ND                       −                ND          Goering et al., [@B54]
                 ST36-II \[2A\]                                    30                   ND                       −                ND          
                 ST1173-IV \[2B\]                                  5                    t064                     −                ND          Shittu et al., [@B111]
                 ST1338-IV \[2B\]                                  5                    t064                     −                ND          
                 ST239-III \[3A\]                                  5                    t037                     −                ND          
                 ST5-III \[3A\]                                    5                    t045                     −                ND          
                 ST239-III \[3A\]                                  5                    t037                     −                ND          Moodley et al., [@B79]
                 ST612-IV \[2B\]                                   5                    t064                     −                ND          
                 ST5-I \[1B\]                                      5                    t045                     −                ND          
                 ST22-IV \[2B\]                                    22                   t032                     −                ND          
                 ST22-IV \[2B\]                                    22                   t891                     \+               ND          
                 ST36-II \[2A\]                                    30                   t012                     −                ND          
                 ST239-III \[3A\]                                  5                    t037                     −                ND          Jansen van Rensburg et al., [@B61]
                 ST5-I \[1B\]                                      5                    t045                     ND               ND          
                 ST650-IV \[2B\]                                   5                    t002                     ND               ND          
                 ST612-IV \[2B\]                                   5                    t064, t1443, t2196       ND               ND          
                 ST72-NT                                           5                    t3092                    ND               ND          
                 ST22-IV \[2B\]                                    22                   t032                     ND               ND          
                 ST36-II \[2A\]                                    30                   t012, t021               ND               ND          
                 ST5-I \[1B\]                                      5                    t002                     −                II          Oosthuysen et al., [@B88]
                 ST8-V \[5C\]                                      5                    t064                     −                I           
                 ST612-IV \[2B\]                                   5                    t064                     \+               I           
                 ST239-III \[3A\]                                  5                    t021                     −                I           
                 ST22-V \[5C\]                                     22                   t891                     \+               I           
                 ST22-IV \[2B\]                                    22                   t891                     −                I           
                 ST36-II \[2A\]                                    30                   t021                     −                III         
  São Tome       ST5-IVa \[2B\]                                    5                    t105                     −                II          Conceição et al., [@B30]
  and Príncipe   ST105-II \[2A\]                                   5                    t002                     −                II          
                 ST8-V \[5C\]                                      5                    t451                     −                I           
                 ST8-IV \[2B\]                                     5                    t451                     −                I           
                 ST88-IVa \[2B\]                                   88                   t186, t786               −                III         
  Tunisia        ST80-IV \[2B\]                                    80                   t044                     \+               III         Ben Nejma et al., [@B14]
                 ST80-IV \[2B\]                                    80                   t044                     \+               III         Ben Nejma et al., [@B15]
                 ST728-IVc \[2B\]                                  80                   t042, t044               \+               III         Kechrid et al., [@B65]
                 ST8-IVc \[2B\]                                    5                    t062                     \+               II          
                 ST80-IVc \[2B\]                                   80                   t203                     \+               III         Ben Slama et al., [@B18]
                 ST1-NT                                            5                    t035                     −                III         Ben Jomàa-Jemili et al., [@B13]
                 ST247-I \[1B\]                                    5                    t040                     −                I           
                 ST239-III \[3A\]                                  5                    t003                     −                I           
                 ST241-III \[3A\]                                  5                    t125                     −                I           
                 ST97-NT                                           5                    t003                     −                I           
                 ST1819-I \[1B\]                                   5                    NS                       −                I           
                 ST80-IVc \[2B\]                                   80                   t070                     \+               III         
                 ST2563-IVc \[2B\]                                 80                   t070                     \+               III         
                 ST1440-IVc \[2B\]                                 80                   t070                     \+               III         
                 ST80-IVc \[2B\]                                   80                   t1021                    −                II          
                 ST80-IVc \[2B\]                                   80                   ND                       −                III         
                 ST22-NT                                           22                   t998                     −                II          
                 ST45-NT                                           45                   ND                       −                I           
                 ST153-NT                                          80                   NST                      \+               III         
                 ST153-NT                                          80                   t044                     ND               III         Gharsa et al., [@B52]

agr, Accessory gene regulator; CC, Clonal complex; NT, Non typeable; ND, Not determined; NST, New spa type; PVL, Panton-Valentine Leukocidin genes; SCCmec, Staphylococcal chromosomal cassette mec element; ST, Sequence type; spa, Staphylococcus aureus protein A gene; X^a^, Unknown SCCmec type other than I, II, III, IV or V;

Clones isolated from pigs;

+, PVL positive; −, PVL negative.

Community- and hospital- acquired MRSA
--------------------------------------

Overall, 51% (29/57) of the eligible studies provided the potential source (hospital- or community-associated) of the MRSA strains. Only 17.5% (10/57) reported MRSA from community settings (Table [1](#T1){ref-type="table"}). USA300 (ST8-IV \[2B\]) and other related sequence types were noted both in health care and community settings in nine African countries (Tables [1](#T1){ref-type="table"}, [2](#T2){ref-type="table"}). The "Brazilian/Hungarian clone" (ST239-III \[3A\]) was associated with hospital-acquired infections in nine countries (Tables [1](#T1){ref-type="table"}, [2](#T2){ref-type="table"}). Furthermore, the "West Australia MRSA-2" (ST88-IV \[2B\]) was reported in community- and hospital-acquired infections in several African countries (Table [2](#T2){ref-type="table"}).

Detection of panton-valentine leukocidin (PVL) genes
----------------------------------------------------

The screening for PVL-associated genes (lukF-PV and lukS-PV) was carried out in 44 studies, and the detection of PVL genes was only reported in 32 studies (Table [1](#T1){ref-type="table"}). In animals, PVL-positive MRSA (ST5) was described in nasal samples of pigs from Senegal (Fall et al., [@B47]). In humans, the proportion of PVL-positive MRSA carriage and/or infections ranged from 0.3 to 100%. Studies from Algeria and Tunisia reported higher PVL prevalence while investigations from South Africa reported the lowest prevalence (Table [3](#T3){ref-type="table"}). Overall, PVL-positive MRSA were more frequently reported with skin and soft tissue infections, and community-associated clones (Tables [1](#T1){ref-type="table"}, [2](#T2){ref-type="table"}). There was no report on the role of PVL in necrotizing pneumonia caused by MRSA in Africa.

###### 

**Panton-Valentine Leukocidin prevalence as reported by the eligible studies with sample size of 30 or above**.

  **Country**                                    **PVL positive (no. positive/total tested)**   **Prevalence (%)**   **References**
  ---------------------------------------------- ---------------------------------------------- -------------------- ----------------------------------
  Algeria                                        46/61                                          75                   Ramdani-bouguessa et al., [@B95]
                                                 19/64                                          30                   Ouchenane et al., [@B90]
                                                 94/122                                         77                   Antri et al., [@B6]
  Kenya                                          14/69                                          20                   Maina et al., [@B74]
  Libya                                          10/35                                          29                   Al-haddad et al., [@B5]
  Nigeria                                        33/70                                          47                   Ghebremedhin et al., [@B53]
  South Africa                                   1/320                                          0.3                  Moodley et al., [@B79]
                                                 4/97                                           4                    Makgotlho et al., [@B75]
                                                 5/56                                           9                    Oosthuysen et al., [@B88]
  Tunisia                                        68/72                                          94                   Ben Nejma et al., [@B16]
                                                 64/64                                          100                  Ben Nejma et al., [@B15]
                                                 43/69                                          62                   Ben Jomàa-Jemili et al., [@B13]
  Uganda                                         30/41                                          73                   Kateete et al., [@B64]
  Multicenter[^\*^](#TN8){ref-type="table-fn"}   20/86                                          23                   Breurec et al., [@B22]

Multicenter study which included Cameroon, Madagascar, Morocco, Niger and Senegal.

PVL, Panton-Valentine Leukocidin; no., Number.

MRSA clones reported in africa using the current eBURST scheme
--------------------------------------------------------------

Figures [2](#F2){ref-type="fig"}, [3](#F3){ref-type="fig"} summarize the MRSA clones identified in Africa based on MLST CCs. By the current eBURST scheme, six main CCs were identified: CC5, CC22, CC30, CC45, CC80, and CC88. In addition, a number of diverse *spa* types were identified among the MRSA clones in Africa (Table [2](#T2){ref-type="table"}), but the distribution of *spa* types t042 and t044 (associated with CC80-IV \[2B\]) appear to be limited to three North African (Algeria, Egypt and Tunisia) countries (Table [2](#T2){ref-type="table"}).

![**MRSA clones reported in Africa**. Each clonal complex is annotated with a colored circle. The number of studies conducted in each country is also indicated.](fmicb-06-00348-g0002){#F2}

![**The minimum spanning tree was constructed by the goeBURST algorithm using the Phyloviz software v1.1 (<http://www.phyloviz.net/>)**. The allelic profiles were downloaded from the MLST website (<http://saureus.mlst.net/>) which included the MRSA sequence types (STs) described in this review as well as 223 randomly selected STs (from each CC) based on the differences in their allelic profiles. The Group founder is colored in green and the related STs are in blue. The six main CCs described in this review are indicated by the dotted lines and the STs reported in Africa are indicated by the red color.](fmicb-06-00348-g0003){#F3}

Clonal complex 5
----------------

This clonal complex is considered the largest group based on the eBURST scheme (Figure [3](#F3){ref-type="fig"}). It was subdivided into three main clusters and designated as CC5-ST1, ST5, and ST8.

MRSA CC5 with sequence type 1
-----------------------------

This group was reported in Nigeria (Raji et al., [@B94]) and Tunisia (Ben Jomàa-Jemili et al., [@B13]). The clonal type included the PVL-positive ST1-V \[5C\] isolated from patients in a tertiary hospital in Nigeria (Raji et al., [@B94]), and the PVL-negative ST1 with a non-typeable SCC*mec* element (*spa* type t035 and *agr* type III) identified in Tunisia (Ben Jomàa-Jemili et al., [@B13]). In addition, an ST1 related sequence type (ST772-V \[5C\]), "the Bengal-Bay clone" has been described in Nigeria (Raji et al., [@B94]).

MRSA CC5 with sequence type 5
-----------------------------

This clone was documented in 14 studies and consisted of diverse SCC*mec* elements (Table [2](#T2){ref-type="table"}). The ST5-I \[1B\]/III \[3A\] were identified from clinical samples in health care institutions in South Africa (Shittu et al., [@B111]; Moodley et al., [@B79]; Jansen van Rensburg et al., [@B61]; Oosthuysen et al., [@B88]). ST5-II \[2A\] has been described in Nigeria (Raji et al., [@B94]), and Senegal (Breurec et al., [@B22]). ST5-IV \[2B\]-PVL-positive was the dominant clone in hospitalized patients with skin and soft tissue infections in Dakar, Senegal (Breurec et al., [@B22]). In addition, ST5-IV \[2B\] was detected from nasal samples of pigs in the same geographical area (Fall et al., [@B47]). ST5-IV \[2B\] has also been identified in Algeria (Ramdani-bouguessa et al., [@B95]), Gabon (Schaumburg et al., [@B102]; Ateba Ngoa et al., [@B7]), Morocco (Breurec et al., [@B22]), and South Africa (Essa et al., [@B45]), while the SCC*mec* IVa \[2B\] variant was recovered from hospitalized patients in Algeria (Ramdani-bouguessa et al., [@B95]; Bekkhoucha et al., [@B9]), Angola (Conceição et al., [@B29]), and São Tomé and Príncipe (Conceição et al., [@B30]). Moreover, ST5-IVa \[2B\] was reported from nasal samples of apparently healthy-hospital workers in Angola (Conceição et al., [@B29]). Other ST5 and related clones identified are ST5-V \[5C\] in Angola (Conceição et al., [@B29]), Cameroon (Breurec et al., [@B22]), and Nigeria (Shittu et al., [@B112]), ST72-SCC*mec*-NT in South Africa (Jansen van Rensburg et al., [@B61]), ST72-V \[5C\] in Angola and Ghana (Egyir et al., [@B38]; Egyir et al., [@B39]; Conceição et al., [@B29]), and ST105-II \[2A\] from a patient in São Tomé and Príncipe (Conceição et al., [@B30]). Furthermore, ST650-IV \[2B\] was detected from clinical samples in health care institutions in South Africa (Jansen van Rensburg et al., [@B61]). Finally, ST2629-V \[5C\] was described in Angola (Conceição et al., [@B29]).

MRSA CC5 with sequence type 8
-----------------------------

MRSA assigned to this clone are widespread and diverse across Africa as evidenced in 27 studies (Table [2](#T2){ref-type="table"}). The first known early or ancestral clone, ST250-I \[1B\], was mainly associated with hospital-acquired infections in Ibadan, South-West Nigeria (Ghebremedhin et al., [@B53]), and recently observed in Ghana (Egyir et al., [@B39]). ST8-II \[2A\] was only described in the KwaZulu-Natal region of South Africa (Essa et al., [@B45]), while a number of investigations reported ST8-IV \[2B\] in Angola (Conceição et al., [@B29]), Cameroon (Breurec et al., [@B22]), Gabon (Schaumburg et al., [@B102]; Ateba Ngoa et al., [@B7]), Ghana (Egyir et al., [@B39]), Madagascar (Breurec et al., [@B22]), Nigeria (Adesida et al., [@B1]; Shittu et al., [@B113]), São Tomé and Príncipe (Conceição et al., [@B30]) and South Africa (Essa et al., [@B45]). The MRSA isolates from Angola possessed the SCC*mec* type IVd element (Conceição et al., [@B29]). ST612-IV \[2B\], a double locus variant (dlv) of ST8-IV \[2B\], and only recently reported as PVL-positive (Oosthuysen et al., [@B88]), is widespread across South Africa (Goering et al., [@B54]; Moodley et al., [@B79]; Jansen van Rensburg et al., [@B61]; Oosthuysen et al., [@B88]), alongside other variants such as ST1173/ST1338-IV \[2B\] (Shittu et al., [@B111]). The ST8-IV \[2B\] clone in South Africa was identified from a variety of clinical infections, in particular, bacteraemia, skin and soft tissue and wound infections (Shittu et al., [@B111]; Moodley et al., [@B79]; Jansen van Rensburg et al., [@B61]; Oosthuysen et al., [@B88]). An ST8-IVc \[2B\] strain (PVL-positive; *spa* type t062) was identified from a 4 day old male child with community-acquired invasive infection in Tunisia (Kechrid et al., [@B65]). Furthermore, ST8-V \[5C\] was described in Algeria (Antri et al., [@B6]), Angola (Conceição et al., [@B29]), Ghana (Egyir et al., [@B38]), Nigeria (Shittu et al., [@B112], [@B113]; Raji et al., [@B94]), São Tomé and Príncipe (Conceição et al., [@B30]), and South Africa (Oosthuysen et al., [@B88]). Other STs observed within the CC5-ST8 cluster include ST8-SCC*mec-NT* in Gabon (Schaumburg et al., [@B99]) and Nigeria (Shittu et al., [@B113]), ST94-IV \[2B\] described in Nigeria (Shittu et al., [@B112]) and ST97-SCC*mec*-NT in Tunisia (Ben Jomàa-Jemili et al., [@B13]). In addition, ST247-I \[1B\] was reported only in Tunisia (Ben Jomàa-Jemili et al., [@B13]) and Nigeria (Raji et al., [@B94]), ST637-III \[3A\] in Algeria (Ramdani-bouguessa et al., [@B95]), ST1819-I \[1B\] in Tunisia (Ben Jomàa-Jemili et al., [@B13]), and ST2021-V \[5C\] in Ghana (Egyir et al., [@B39]).

The "Brazilian/Hungarian clone" (ST239-III \[3A\]) is an hybrid of CC30 and CC8 based on a single large chromosomal replacement (Robinson and Enright, [@B96]), and ST241-III \[3A\] is a single locus variant (slv) of ST239-III \[3A\]. These two STs were identified concurrently in Algeria (Ramdani-bouguessa et al., [@B95]), Morocco, Niger and Senegal (Breurec et al., [@B22]), and Tunisia (Ben Jomàa-Jemili et al., [@B13]). ST239-III \[3A\] has also been described in Ghana (Egyir et al., [@B39]) and Kenya (Aiken et al., [@B2]), and consistently since 2001 in South Africa (Essa et al., [@B45]; Shittu et al., [@B111]; Moodley et al., [@B79]; Jansen van Rensburg et al., [@B61]; Oosthuysen et al., [@B88]). A recent study detected ST239 with the SCC*mec* type III~*mercury*~ \[3A\] in a tertiary health care facility in South-West Nigeria (Raji et al., [@B94]). ST241-III \[3A\] is the dominant clone in North-East Nigeria (Okon et al., [@B84]; Shittu et al., [@B112], [@B113]). Interestingly, three SCC*mec* variants, ST239-IVa \[2B\], ST239/ST241-V \[5C\], and ST241-IV \[2B\], and associated with hospital-acquired infections were reported in Algeria (Ramdani-bouguessa et al., [@B95]), Niger (Breurec et al., [@B22]), and Nigeria (Ghebremedhin et al., [@B53]).

Clonal complex 22
-----------------

In Africa, ST22 was identified only in Algeria (Ramdani-bouguessa et al., [@B95]), South Africa (Moodley et al., [@B79]; Jansen van Rensburg et al., [@B61]; Oosthuysen et al., [@B88]), and Tunisia (Ben Jomàa-Jemili et al., [@B13]). ST22-IV \[2B\] was related with hospital-associated infections in the Western Cape and KwaZulu-Natal provinces of South Africa. A variant of ST22 (ST22-V \[5C\]-PVL-positive) was also reported in an hospital in Western Cape, South Africa (Oosthuysen et al., [@B88]). The ST22 identified in Tunisia possessed a non-typeable SCC*mec* element (Ben Jomàa-Jemili et al., [@B13]). Besides, an ST636-SCC*mec*-NT isolate has also been reported in Algeria (Ramdani-bouguessa et al., [@B95]).

Clonal complex 30
-----------------

ST30-IVa \[2B\]-PVL-positive, also known as "South-West Pacific clone," has been reported in Egypt (Enany et al., [@B42]), and a multicenter African study identified ST30-V \[5C\] only in Antananarivo, Madagascar (Breurec et al., [@B22]). The hospital associated ST36-II \[2A\] (UK-EMRSA-16), was described only in South Africa (Goering et al., [@B54]; Moodley et al., [@B79]; Jansen van Rensburg et al., [@B61]; Oosthuysen et al., [@B88]), while ST39-II \[2A\] a dlv was identified in an hospital in Algiers, Algeria (Djoudi et al., [@B35]), and Ile-Ife, South-West Nigeria (Shittu et al., [@B113]). MRSA assigned with these groups (ST36-II \[2A\] and ST39-II \[2A\]) were PVL-negative. Furthermore, two SCC*mec* variants, ST37-IVa \[2B\] and ST37-III \[3A\], were reported in Algeria (Ramdani-bouguessa et al., [@B95]) and Nigeria (Shittu et al., [@B113]), respectively.

Clonal complex 45
-----------------

ST45-IV \[2B\], the "Berlin clone," was detected in an hospital in the KwaZulu-Natal (South Africa) during a multicenter surveillance study (Essa et al., [@B45]) and ST45-V \[5C\] was reported in mother-infant pairs in Gabon (Schaumburg et al., [@B99]). An MRSA with a non-typeable SCC*mec* associated with community-acquired infections has been identified in Tunisia (Ben Jomàa-Jemili et al., [@B13]). Finally, ST508-V \[5C\], a slv to ST45, and also associated with community-acquired infections was described in Ghana (Egyir et al., [@B37]).

Clonal complex 80
-----------------

The CC80 was limited to three North African countries: Algeria, Egypt, and Tunisia (Table [2](#T2){ref-type="table"}). The European clone, ST80-IV \[2B\]-PVL-positive, was first described in Algeria from both hospitalized and outpatients (Ramdani-bouguessa et al., [@B95]), and has continued to be the leading clone in the country (Ramdani-bouguessa et al., [@B95]; Bekkhoucha et al., [@B9]; Antri et al., [@B6]; Djoudi et al., [@B35]). ST80-IVc \[2B\] has been identified in Egypt (Enany et al., [@B42]), and Tunisia (Ben Slama et al., [@B18]; Ben Jomàa-Jemili et al., [@B13]). In addition, sequence types related to ST80 have been recovered from human clinical samples (ST153-SCC*mec*-NT, ST728-IVc \[2B\], ST1440-IVc \[2B\], and ST2563-IVc \[2B\]) (Kechrid et al., [@B65]; Ben Jomàa-Jemili et al., [@B13]), and nasal specimen of healthy sheep (ST153-SCC*mec*-NT) (Gharsa et al., [@B52]) in Tunisia. The afore-mentioned sequence types, ST728, ST1440 and ST2563 belonged to accessory gene regulator (agr) type III and were PVL-positive. Moreover, a PVL-negative ST80-IVc \[2B\] with *agr* type II has also been detected in Tunisia (Ben Jomàa-Jemili et al., [@B13]), and a PVL-negative ST635-IV \[2B\] in Algeria (Ramdani-bouguessa et al., [@B95]).

Clonal complex 88
-----------------

The "West Australia MRSA-2 clone" (WA-MRSA-2), ST88-IV \[2B\], was reported in both hospital and community settings in eight African countries; Angola (Conceição et al., [@B29]), Cameroon (Breurec et al., [@B22]), Gabon (Schaumburg et al., [@B102]; Ateba Ngoa et al., [@B7]), Ghana (Egyir et al., [@B38], [@B39]), Madagascar (Breurec et al., [@B22]), Niger (Breurec et al., [@B22]), Nigeria (Ghebremedhin et al., [@B53]; Shittu et al., [@B113]; Raji et al., [@B94]) and Senegal (Breurec et al., [@B22]). The MRSA isolates from Angola possessed an SCC*mec* IVa \[2B\] element (Conceição et al., [@B29]). PVL-positive ST88-IV \[2B\] were detected in Nigeria (Ghebremedhin et al., [@B53]), and an SCC*mec* subtype ST88-IVa \[2B\] was identified among three health care workers and a patient in São Tomé and Príncipe (Conceição et al., [@B30]). The ST88-IV \[2B\] with *spa* type t3489 was also recovered from nasal samples of swine in Senegal (Fall et al., [@B47]). In addition, an SCC*mec* non-typeable ST88 was described from an out-patient in Algeria (Bekkhoucha et al., [@B9]), and a strain related to WA-MRSA-2 (ST1289-IV \[2B\]) was identified in Yaoundé, Cameroon (Breurec et al., [@B22]).

Other clonal complexes
----------------------

CC7, CC121, and CC152 have been reported in Africa. The PVL-negative ST789 (assigned with CC7) was identified in Angola (with SCC*mec* IV \[2B\]) (Conceição et al., [@B29]). However, in Ghana, ST789 was PVL-positive and carried an SCC*mec* IV element \[2B\] (Egyir et al., [@B39]). An ST1010-PVL-positive (CC121) with non-typeable SCC*mec* element has only been described in Egypt (Enany et al., [@B42]). Furthermore, PVL-positive MRSA assigned to CC152 (ST152-SCC*mec*-NT) was reported in Nigeria (Shittu et al., [@B113]).

Discussion {#s4}
==========

MRSA has been reported in Africa, at least since 1978 (Scragg et al., [@B103]). This systematic review showed that adequate data on the molecular epidemiology of MRSA are limited, with reports from only 15 of the 54 African countries. No *spa* type was dominant, however, t042 and t044 were the major *spa* types identified in three North African countries (Table [2](#T2){ref-type="table"}). Moreover, we did not observe a clear distinction between hospital- and community-associated MRSA clones in Africa which is in agreement with other investigations worldwide (Fossum Moen et al., [@B48]; Pasquale et al., [@B91]; Sherwood et al., [@B107]; Tavares et al., [@B119]). In this systematic review, the use of the current eBURST scheme grouped several African MRSA CCs (CC1, CC5, CC8, and CC7) into a single cluster, (CC5). This raises some concern on a suitable method for discrimination and grouping of *S. aureus* isolates. To overcome the above mentioned issue, whole genome sequencing approach might be the alternative (Dabul and Camargo, [@B32]).

Although a combination of factors could be responsible for the dissemination of clones between continents, increased movement of human population within or between countries might be one of the potential factors (Rogers et al., [@B97]). International travel could play a significant role in the transmission of MRSA, particularly the replacement of existing MRSA with fitter and more transmissible clones (Zhou et al., [@B125]). We observed that the predominant hospital-associated epidemic clones, EMRSA-15 \[ST22-IV \[2B\]) and (EMRSA-16 \[ST36-II \[2A\]), in the United Kingdom (UK) (Johnson et al., [@B63]) were reported only in South Africa (Goering et al., [@B54]; Moodley et al., [@B79]; Jansen van Rensburg et al., [@B61]; Oosthuysen et al., [@B88]). Moreover, ST80-IV \[2B\] (the European clone) has consistently been recognized as the predominant PVL-positive MRSA clone in North Africa (Ramdani-bouguessa et al., [@B95]; Bekkhoucha et al., [@B9]; Ben Nejma et al., [@B14], [@B15]; Enany et al., [@B42]; Antri et al., [@B6]; Ben Slama et al., [@B18]; Ben Jomàa-Jemili et al., [@B13]; Djoudi et al., [@B35]). A recent report based on whole genome analysis provided strong evidence that the European ST80-IV \[2B\] was derived from a PVL-positive MSSA ancestor in sub-Saharan Africa that acquired the SCC*mec* IV element, and clonal spread was enhanced by increased transnational movement (Stegger et al., [@B118]). However, the factors responsible for the limited spread of the ST80-IV \[2B\] only in North Africa observed so far are unclear.

The SCC*mec* IV (and its subtypes) and SCC*mec* V were identified in several MRSA clones, and ST5 and ST8 clearly showed more diversity in terms of SCC*mec* types compared with other STs in Africa. The success of these SCC*mec* types (IV and V) could be due to their small sizes and low fitness costs (Enright et al., [@B43]; Okuma et al., [@B86]; Monecke et al., [@B78]). It is also noteworthy that the SCC*mec* types IVa and IVc were identified in genetically unrelated clones, e.g., ST5-IVa \[2B\] (CC5) in Algeria (Ramdani-bouguessa et al., [@B95]; Bekkhoucha et al., [@B9]), São Tomé and Príncipe (Conceição et al., [@B30]), ST8-IVc \[2B\] in Tunisia (CC5) (Kechrid et al., [@B65]), and ST37-IVa \[2B\] (CC30) in Algeria (Ramdani-bouguessa et al., [@B95]). This might suggest horizontal gene transfer or independent acquisition (Mašlaòová et al., [@B76]). Another interesting observation was the detection of the SCC*mec* type IVa and V in the hospital-associated ST239/ST241-III \[3A\] in Algeria (Ramdani-bouguessa et al., [@B95]), Nigeria (Ghebremedhin et al., [@B53]), and Niger (Breurec et al., [@B22]). Since ancient MSSA strains for this ST have not been reported (Enright et al., [@B43]), our observation suggests that acquisition of these SCC*mec* types by MSSA is less likely, and points to the possible replacement of SCC*mec* type III with IV and V on the ST239/241 genome (Li et al., [@B70]).

Data on the epidemiology of MRSA in animals are limited in Africa (EL Seedy et al., [@B41]; Fall et al., [@B47]; Gharsa et al., [@B52]). Moreover, the genetic relatedness between human and animal MRSA has not been investigated (Table [2](#T2){ref-type="table"}). It should be noted, however, that human-associated ST5-IV \[2B\], ST88-IV \[2B\], and ST153-SCC*mec-*NT have been reported from animals in Tunisia (Gharsa et al., [@B52]) and Senegal (Fall et al., [@B47]). Recently, human-associated *S. aureus* lineages were described in captive Chimpanzees in Gabon, Madagascar, Uganda and Zambia (Schaumburg et al., [@B101], [@B100]; Nagel et al., [@B82]). Notably, a likely case of *S. aureus* transmission from a veterinarian to a chimpanzee from the same sanctuary was demonstrated (Schaumburg et al., [@B101]). Zoonotic transmission may constitute a major concern in Africa, where there is often substantial exposure to domesticated animals (Fall et al., [@B47]; Gharsa et al., [@B52]). Furthermore, animal-adapted clones might undergo further host-adaptive evolutionary changes, which could result in an epidemic spread of new and more virulent strains in the human population (Spoor et al., [@B116]). Other risk factors for animal to human MRSA transmission, which include contaminated environment (Verkade and Kluytmans, [@B123]) and meat products (Hamid and Youssef, [@B55]), have not been investigated in Africa. Livestock-associated MRSA are widespread in Europe, but the transmission of these strains to humans is either rare or limited to people with direct contact with MRSA infected/carrier animals (Verkade and Kluytmans, [@B123]). Using whole genome sequencing, evidence of zoonotic transmission of MRSA harboring *mecC* was reported in Denmark (Harrison et al., [@B56]). The *mecC*-positive MRSA, initially known as a livestock MRSA belonging to the CC130, is recognized in both animals and humans in Europe (Paterson et al., [@B92]). In addition, this clone has been implicated in severe infections in humans (Paterson et al., [@B93]), resulting in one death (García-Garrote et al., [@B50]). The clinical importance of *mecC*-positive MRSA is not yet clear in Africa as data is unavailable. Therefore, we suggest that surveillance for MRSA should include detection of the *mecC* gene where *mecA* is not detected in resistant isolates.

This systematic review did not seek to provide comprehensive information on the burden of PVL-positive MRSA in Africa. However, it provided some interesting observations on their epidemiology in Africa such as the identification of PVL-positive isolates assigned with CC7 (originally classified with CC152) in Ghana (Egyir et al., [@B37]), CC88-IV \[2B\] in Cameroon (Breurec et al., [@B22]) and Nigeria (Ghebremedhin et al., [@B53]), ST612-IV \[2B\] in South Africa (Oosthuysen et al., [@B88]), and CC152 in Nigeria (Shittu et al., [@B113]). Until now, CC152 was only described in the Balkan region (Francois et al., [@B49]). The mode of acquisition of the *mecA* gene by ST152 is still unknown, but it might be explained by either its introduction through international travel or the acquisition of the methicillin resistance gene by PVL-positive MSSA, which is prevalent in West and Central Africa (Ruimy et al., [@B98]; Okon et al., [@B84]; Breurec et al., [@B21]; Schaumburg et al., [@B102]; Shittu et al., [@B112], [@B113]; Egyir et al., [@B37]). These observations highlight the need for further surveillance data (including information on community-acquired necrotizing pneumonia) to understand the epidemiology of PVL-associated *S. aureus* in both hospital and community settings on the African continent.

Conclusion {#s5}
==========

A number of pandemic MRSA clones were identified in Africa. In contrast, some MRSA clones are limited to specific countries or regions. Although the eBURST snapshot provided a description of the relationship between the MRSA clones reported in Africa and other lineages submitted into the MLST database from other continents, the objective of this review was not to understand the origin of MRSA clones in Africa, as this will require in depth analysis like whole genome sequencing. However, it did show that CC5 is the largest group and predominant in Africa. Nevertheless, the limited data available on MRSA in Africa draw attention to the need for increased surveillance of MRSA and molecular epidemiological studies. We strongly recommend improved co-operation between clinicians and microbiologists in Africa. This synergy could provide an understanding on the local epidemiology of MRSA. In addition, we strongly advocate the establishment of effective diagnostic microbiology facilities that will incorporate high-throughput technologies for monitoring the clonal expansion and dissemination of MRSA. In the meantime, increased networking through collaboration with *S. aureus* reference centers could provide support for genotyping services to African countries with limited resources. Finally, population-based surveillances for MRSA are needed to evaluate the situation of community associated MRSA as well as studies on MRSA from animal hosts. To understand the origin of the newly emerged clones, MSSA genotyping needs to be incorporated with MRSA surveillance studies.
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